Compare Medpace Holdings Inc (MEDP) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 2,913,938). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| MEDP | QYLD | |
|---|---|---|
Market Cap | $16.82B | $8.49B |
Volume | 223,093 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $630.19 | $18.69 |
52-Week Low | $393.42 | $16.70 |
Typical Hold Time | 14 Days | 51 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
QYLD trades at $18.66, showing minimal daily movement with a slight decline of -0.11%. The ETF maintains a consistent monthly dividend distribution of $0.18 per share, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including overbought RSI readings. Recent news highlights QYLD's high yield strategy but raises concerns about long-term capital erosion and tax implications.
QYLD offers high monthly income through covered call strategies but faces significant risks from capped upside potential and principal erosion. The ETF's distribution sustainability depends on Nasdaq volatility, with recent articles warning about declining option premiums. Investors should weigh the trade-off between immediate income and long-term capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
